Welcome to the First 2021 Issue of The CLL Society Tribune
Spring is in the air and we are still locked down but sense a cautious optimism that the post-pandemic world may soon be near, even for the most vulnerable of us who either have CLL or are caring for someone with this diagnosis.
We are pleased to bring you the first edition of the 2021 CLL Society Tribune, full of articles from patients and experts to inspire, educate, and guide you towards advocating for your best care, wherever you are in your CLL journey.
Stay strong.
We are all in this together.
Patty Koffman
Co-founder & Communications Director
CLL Society
Rare Always Finds Me
Read about John’s life events, his CLL journey, and his upbeat story about how nothing in this life is random. Every event in one’s life, both good and bad, happens for a reason and makes you a better person. Read more
Update: 3.3 Years Captivate Trial, 4.3 years with CLL
Read Mark’s exciting report how he is still MRD Undetectable (UMRD) in the blood after 3 years in the Captivate clinical trial! Read more
A Patient Story
By An Anonymous CLL Patient
Read about this patient’s journey from diagnosis in 2012 to today – never allowing CLL to be in control. Read more
Reader Poll Results: CAR-T Therapy Survey
During December 2020 through March 2021, the CLL Society conducted a poll among readers of The CLL Society Tribune covering CAR-T therapy. See the results!
Our New Survey: Treatment Decisions
Please take a moment to complete our brief, reader survey covering Treatment Decisions. Read more.
CLL Facts: What’s In a Name?
By Brian Koffman, MDCM (retired), MSEd
Dr. Koffman discusses how drugs get their brand names. Read more
White Blood Cells and Differential for CLLers
By Susan J. Leclair, PhD, CLS (NCA)
Learn more about the WBC on your CBC report and the types of white blood cell found in the peripheral blood. Read more
Driving CARs to the Clinic for Standard Medical Management of CLL
Dr. Fraietta shares how CAR-T cell therapy is well-positioned to become part of routine medical management of CLL. Read more
ASH 2020: Dr. Anthony Mato Discusses the Impact of del(17p) On Survival of Patients with CLL Treated with First-Line Ibrutinib
At the virtual ASH meeting which was held December 2020, Dr. Brian Koffman interviewed Dr. Anthony Mato about new research evaluating the efficacy of ibrutinib as a first-line treatment for patients with CLL and del(17p). Watch The Interview
Questions submitted by readers and answered by our CLL Society experts.
By Richard Furman, MD
Dr. Richard Furman of Weill-Cornell Medical College answers readers’ questions submitted to the CLL Society. Read more
By Thomas E Henry III, MBA, RPh, CPh
Thomas E Henry III, MBA, RPh, CPh from Burlington Consulting Associates answers readers’ pharmacy questions submitted to the CLL Society. Read more
By Susan J. Leclair, PhD, CLS (NCA)
Susan J. Leclair from University of Massachusetts Dartmouth answers readers’ lab scientist questions submitted to the CLL Society. Read more
The CLL Society Tribune is looking for your contribution including articles, storytelling, poems, drawings, or other creative mediums. Please share!
Email support@cllsociety.org with your interest!
The CLL Society Tribune is made possible in part by grant support from AbbVie and Adaptive Biotechnologies.
DISCLAIMER
The CLL Society does not provide medical advice or endorsements. Unless explicitly stated otherwise, all content in the CLL Tribune is the opinion or information of its author, not the CLL Society. This newsletter is for reference and educational purposes only and is not a substitute for medical advice. We do not guarantee the accuracy of any of the materials. Always contact your own doctor or other professional healthcare provider if you have any questions concerning your or your family’s health. Everyone’s circumstances are different.